Table 1. Median-effect doses (IC50) of salinomycin or temozolomide in glioma cell lines.

IC50
	SLM	TMZ
GSC11	5·10−7 M	8·10−4 M
GSC23	1·10−7 M	2·10−6 M
GSC7–2	5·10−8 M	2·10−4 M
GSC6–27	1·10−7 M	3·10−6 M
GSC5–22	1·10−8 M	2·10−4 M
GSC2	1·10−7 M	1·10−5 M
GSC231	6·10−8 M	1·10−5 M
GSC7–11	1·10−7 M	3·10−4 M
GSC10–6	3·10−8 M	2·10−4 M
GSC11–28	7·10−8 M	4·10−4 M
GSC229	7·10−7 M	3·10−4 M
U87 MG	5·10−6 M	6·10−4 M
T98G	7·10−6 M	6·10−4 M
U373	8·10−7 M	4·10−4 M
U251 MG	4·10−6 M	out of range
PBT7	2·10−7 M	6·10−4 M
KNS42	8·10−7 M	out of range
RES186	5·10−6 M	out of range
RES259	1·10−6 M	1·10−4 M
SF188	2·10−7 M	6·10−4 M